ResMed (NYSE:RMD) was downgraded by equities researchers at UBS from a “buy” rating to a “neutral” rating in a research note issued to investors on Tuesday.
Other research analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of ResMed from a “hold” rating to a “buy” rating and set a $99.00 price target on the stock in a research report on Thursday, January 18th. ValuEngine upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Finally, Needham & Company LLC upgraded shares of ResMed from an “underperform” rating to a “hold” rating in a research report on Tuesday, January 23rd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $74.83.
RMD opened at $96.45 on Tuesday. ResMed has a 1-year low of $67.04 and a 1-year high of $104.78. The company has a market capitalization of $13,998.28, a price-to-earnings ratio of 34.20 and a beta of 0.90.
In other news, Director John P. Wareham sold 25,934 shares of the firm’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $102.25, for a total transaction of $2,651,751.50. Following the sale, the director now directly owns 38,934 shares in the company, valued at approximately $3,981,001.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James Hollingshead sold 600 shares of the firm’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $94.01, for a total transaction of $56,406.00. The disclosure for this sale can be found here. Insiders have sold a total of 42,004 shares of company stock worth $4,209,303 over the last 90 days. Insiders own 1.77% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Calton & Associates Inc. purchased a new position in ResMed during the fourth quarter valued at $115,000. Cubist Systematic Strategies LLC purchased a new position in ResMed during the third quarter valued at $113,000. Conning Inc. purchased a new position in ResMed during the fourth quarter valued at $203,000. Commerzbank Aktiengesellschaft FI purchased a new position in ResMed during the fourth quarter valued at $206,000. Finally, Dowling & Yahnke LLC purchased a new position in ResMed during the fourth quarter valued at $208,000. Hedge funds and other institutional investors own 62.38% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://sportsperspectives.com/2018/04/26/resmed-rmd-cut-to-neutral-at-ubs.html.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.